MedTrace Logo

Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy

NCT07491718 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2026-03-24

No results posted yet for this study

Summary

The goal of this research study is to further understand the physiological mechanisms involved in a heart condition called takotsubo cardiomyopathy, also known as broken heart syndrome. Furthermore, the investigators will be assessing the effects different cardiac medications have on these physiological mechanisms.

This will be achieved by performing cardiac MRI scans using a special dye called manganese. Manganese uptake in the heart is altered in patients with takotsubo cardiomyopathy. The investigators will study the effects that different cardiac medications have on manganese uptake.

Conditions

  • Takotsubo Cardiomyopathy

Interventions

DRUG

Bisoprolol

Participants will be randomised to receive Bisoprolol medication.

DRUG

Valsartan

Participants will be randomised to receive Valsartan medication.

DRUG

sacubitril/ valsartan

Participants will be randomised to receive Sacubitril/Valsartan medication first.

DRUG

Dapagliflozin (10mg Tab)

Participants will be randomised to receive Dapaglifozin medication first.

DRUG

No medications

Participants will be randomised to receive no study medication.

Sponsors & Collaborators

  • University of Edinburgh

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-08-08
Primary Completion
2028-08-09
Completion
2028-08-09

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07491718 on ClinicalTrials.gov